Aerobic exercise and intraocular pressure in normotensive and glaucoma patients.
BACKGROUND
With the increasing number of people participating in physical aerobic exercise, jogging in particular, we considered that it would be worth knowing if there are should be limits to the exercise with regard to the intraocular pressure (IOP) of the eyes. The purpose of this study is to check IOP in healthy and primary glaucoma patients after aerobic exercise.


METHODS
145 individuals were subdivided into seven groups: normotensives who exercised regularly (Group A); normotensives in whose right eye (RE) timolol maleate 0.5% (Group B), latanoprost 0.005% (Group C), or brimonidine tartrate 0.2% (Group D) was instilled; and primary glaucoma patients under monotherapy with beta-blockers (Group E), prostaglandin analogues (Group F) or combined antiglaucoma treatment (Group G) instilled in both eyes. The IOP of both eyes was measured before and after exercise.


RESULTS
A statistically significant decrease was found in IOP during jogging. The aerobic exercise reduces the IOP in those eyes where a b-blocker, a prostaglandin analogue or an alpha-agonist was previously instilled. The IOP is also decreased in glaucoma patients who are already under antiglaucoma treatment.


CONCLUSIONS
There is no ocular restriction for simple glaucoma patients in performing aerobic physical activity.
Natsis
Konstantinos
K
Department of Anatomy, Medical School, Aristotle University of Thessaloniki, Greece. natsis@med.auth.gr
Asouhidou
Irene
I
Nousios
George
G
Chatzibalis
Theodosios
T
Vlasis
Konstantinos
K
Karabatakis
Vasilios
V
D000293:Adolescent; D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage; D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage; D000068438:Brimonidine Tartrate; D015444:Exercise / Q000502:physiology*; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects / Q000502:physiology*; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage; D011810:Quinoxalines / Q000008:administration & dosage; D013999:Timolol / Q000008:administration & dosage
D000316:Adrenergic alpha-Agonists; D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D011461:Prostaglandins F, Synthetic; D011810:Quinoxalines; D000068438:Brimonidine Tartrate; D000077338:Latanoprost; D013999:Timolol
Arch Ophthalmol. 1967 Jan;77(1):99-104
4959319
Am J Ophthalmol. 1970 Feb;69(2):245-8
5414005
Ophthalmology. 1992 Jul;99(7):1096-103
1495789
Eur J Appl Physiol Occup Physiol. 1983;52(1):136-8
6686123
Eur J Ophthalmol. 2004 Mar-Apr;14(2):117-22
15134108
Invest Ophthalmol. 1975 Oct;14(10):782-5
241730
Graefes Arch Clin Exp Ophthalmol. 1994 May;232(5):262-4
8045434
Am J Ophthalmol. 1967 Jun;63(6):1673-6
6027342
Invest Ophthalmol Vis Sci. 1992 Sep;33(10):2874-7
1526737
Eye (Lond). 1989;3 ( Pt 4):477-83
2606224
Lancet. 1947 Mar 29;1(6448):402-5
20289886
Eye (Lond). 2001 Oct;15(Pt 5):616-20
11702973
Invest Ophthalmol. 1974 Jan;13(1):74-6
4809513
Invest Ophthalmol Vis Sci. 1994 Oct;35(11):3852-7
7928182
Int Ophthalmol. 1995-1996;19(6):359-62
8970870
Arch Ophthalmol. 1991 Aug;109(8):1096-8
1867551
J Int Med Res. 2002 Jan-Feb;30(1):26-33
11921496
Acta Ophthalmol Scand. 2001 Dec;79(6):567-71
11782220
Invest Ophthalmol Vis Sci. 1999 Apr;40(5):1011-5
10102302
Br J Ophthalmol. 1978 Oct;62(10):679-81
708668
Jpn J Physiol. 1995;45(4):561-9
7474535
Ann Hum Biol. 1995 Nov-Dec;22(6):545-53
8815781
Int J Neurosci. 2006 Mar;116(3):351-60
16484060